Stock Upgrades, Downgrades from TheStreet.com Ratings
Silicon Laboratories (SLAB - Get Report), which makes integrated circuits, has been upgraded to a buy. The company maintains a largely solid financial position with reasonable debt levels, a solid stock performance and growth in net income and earnings per share.
These strengths should outweigh the company's somewhat disappointing return on equity. Silicon Laboratories recently said third-quarter earnings climbed to $20.4 million, or 37 cents per share, from $4.7 million, or 8 cents per share, in the year-ago period. Revenue increased 20% to $87.9 million. The company's stock has surged by 32.2% over the past year to a price level that is now somewhat expensive compared to the rest of its industry. TheStreet.com Ratings believes the company's other strengths justify the higher price levels. Silicon Laboratories had been rated a hold since May 2006.
Pogo Producing (PPP - Get Report), an oil and gas producer, has been upgraded to a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins and solid stock price performance. These factors should outweigh the company's subpar growth in net income. In July, Pogo Producing agreed to be acquired by rival Plains Exploration & Production (PXP) for about $3.6 billion, or $60 a share. Plains Exploration & Production is paying for Pogo in part with its own stock, which also carries a buy rating.
On Thursday Pogo swung to a third-quarter loss of $45.9 million, or 79 cents a share, compared with earnings of $33.4 million, or 58 cents a share, a year ago, as the company recorded charges and sold operations. Pogo Producing had been rated a hold since March.Community Health Systems (CYH - Get Report), which operates hospitals, has been downgraded to a hold. While the company has multiple strengths, such as its robust revenue growth, reasonable valuation levels and growth in earnings per share, profit margins have been poor and the stock performance and return on equity have both been disappointing. In July, Community Health posted second-quarter net income of $53.8 million, or 57 cents a share, up 3% from a year ago, while revenue increased18% to $1.25 billion. The company had recently completed a $5.27 billion buyout of Triad Hospitals. Community Health Systems' stock has declined 14.4% from a year ago. There is nothing in the company's numbers that may help reverse this decline. Despite the decline, the stock is still selling for more than most others in its industry. Community Health Systems had been rated a buy since February. Zimmer Holdings (ZMH - Get Report), which makes orthopedic devices, has been downgraded to hold. The company maintains a largely solid financial position with reasonable debt and valuation levels and revenue growth, but it is also faced with deteriorating net income, disappointing return on equity and weak operating cash flow. Third-quarter net income fell 76% to $44.5 million, or 19 cents a share, due to a $169.5 million charge to resolve a federal investigation regarding relationships between orthopedic providers and consulting surgeons. Revenue climbed 10% to $903.2 million. The stock is now trading at a higher level than a year ago, regardless of the company's weak earnings results and there is currently no conclusive evidence that warrants the purchase or sale of this stock. Zimmer Holdings had been rated a buy since October 2005. Additional ratings changes are listed below.
|Stock Upgrades, Downgrades|
|Company Name||Ticker||Change||New Rating||Former Rating|
|Community Health Systems||CYH||Downgrade||Hold||Buy|
|First Defiance Financial||FDEF||Downgrade||Hold||Buy|
|Palomar Medical Technologies||PMTI||Downgrade||Hold||Buy|
|Comsys IT Partners||CITP||Upgrade||Buy||Hold|
|Source: TheStreet.com Ratings|
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.